¿¬¼ö°­ÁÂ
Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease : 2023-06-10

Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : µ¿°ü 6Ãþ ´ë°­´ç

±³À°ÁÖÁ¦ : Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease

ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ±èÀº¿µ
¿¬¶ôó : 02-3010-3130  

À̸ÞÀÏ : plm3010@amc.seoul.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 60,000¿ø  

ºñ°í 1.Àü¹®ÀÇ »çÀüÁ¢¼ö 50,000¿ø ÇöÀåÁ¢¼ö 60,000¿ø2. ÀüÀÓÀÇ, Àü°øÀÇ ¹× °£È£»ç, ±âŸ µî »çÀüÁ¢¼ö 40,000¿ø ÇöÀåÁ¢¼ö 50,000¿ø

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:00~09:25 Refractory chronic cough: Mechanisms and treatment updates ¼Û¿ìÁ¤(¼­¿ï¾Æ»êº´¿ø ¾Ë·¹¸£±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:25~09:50 The optimal treatment of MAC pulmonary disease Á¶°æ¿í(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:50~10:15 Beyond inhaler: non-pharmacologic treatment in COPD À̼¼¿ø(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

ÈÞ½Ä 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:15~10:30 COFFEE BREAK ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:30~10:40 Importance of accurate nodal staging in stage III NSCLC Áö¿øÁØ(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:40~11:05 Optimal strategy of surgical treatment in stage III NSCLC À±À籤(¼­¿ï¾Æ»êº´¿ø ½ÉÀåÇ÷°üÈäºÎ¿Ü°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:05~11:30 Update of perioperative chemotherapy in stage III NSCLC À±½Å±³(¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:30~11:55 Current practice of radiation therapy in stage III NSCLC ½Å¿µ¼·(¼­¿ï¾Æ»êº´¿ø ¹æ»ç¼±Á¾¾çÇаú)

½Ä»ç 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:55~13:00 LUNCH ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:00~13:25 Updated IPF guideline and PPF (progressive pulmonary fibrosis : radiologic aspect äÀºÁø(¼­¿ï¾Æ»êº´¿ø ¿µ»óÀÇÇаú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:25~13:50 Hopes and concerns about PAH targeted therapy in PH-ILD ÀÌÀç½Â(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:50~14:15 Lung transplantation in ILD patients ±èȣö(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

ÈÞ½Ä 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:15~14:30 COFFEE BREAK ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:30~14:55 Effect of corticosteroid therapy in severe pneumonia and ARDS ÇãÁø¿ø(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:55~15:20 Severe viral pneumonia other than COVID-19 ÃÖ»óÈ£(¼­¿ï¾Æ»êº´¿ø °¨¿°³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 15:20~15:45 Treatment of moderate to severe ARDS ¾ÈÁöȯ(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ : 2018-11-04

±³À°ÀÏÀÚ : 2018-11-04 ±³À°Àå¼Ò : ±×·£µåÈúÆ°È£ÅÚ(È«Àºµ¿) ÄÁº¥¼Ç¼¾ÅÍ ¿Ü ±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 11,028 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,817 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,895 , ´ñ±Û¼ö : 0

[´ë±¸] 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-04-20

±³À°ÀÏÀÚ : 2023-04-20 ±³À°Àå¼Ò : È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸ ÄÁº¥¼ÇȦAB ¿Ü ±³À°ÁÖÁ¦ : 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,976 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,520 , ´ñ±Û¼ö : 0